Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study
Autor: | Vassiliki Douka, Maria Papathanasiou, Vasilis Gianouzakos, Michalis Iskas, Anastasia Athanasiadou, Chrysavgi Lalayanni, Chrysa Apostolou, Zoi Bousiou, Achilles Anagnostopoulos, Stella Bouziana, Despina Mallouri, Eleni Gavriilaki, Varnavas Constantinou, Konstantinos Chatziioannou, Evangelia Yannaki, Damianos Sotiropoulos, Ioanna Sakellari, Ioannis Batsis |
---|---|
Rok vydání: | 2018 |
Předmět: |
Adult
Male medicine.medical_specialty Transplantation Conditioning Thrombotic microangiopathy Cyclophosphamide medicine.medical_treatment Graft vs Host Disease Kaplan-Meier Estimate Hematopoietic stem cell transplantation Infections Gastroenterology Disease-Free Survival Young Adult 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Humans Cumulative incidence Busulfan Retrospective Studies Hematology Thrombotic Microangiopathies business.industry Remission Induction Age Factors General Medicine Precursor Cell Lymphoblastic Leukemia-Lymphoma Total body irradiation medicine.disease Treatment Outcome 030220 oncology & carcinogenesis Adult Acute Lymphoblastic Leukemia Female business Whole-Body Irradiation Follow-Up Studies 030215 immunology medicine.drug |
Zdroj: | Annals of Hematology. 97:1987-1994 |
ISSN: | 1432-0584 0939-5555 |
Popis: | The role of total body irradiation (TBI) in allogeneic hematopoietic stem cell transplantation (HCT) for adult acute lymphoblastic leukemia (ALL) remains controversial. Therefore, we investigated long-term treatment outcomes of transplanted ALL patients aiming to identify prognostic factors and the impact of conditioning. We enrolled consecutive ALL patients transplanted from 1990 to 2016, following TBI- or busulfan (Bu)-based conditioning regimen. We studied 151 ALL patients transplanted in first complete remission (CR) (60), other CR (33), or relapsed/refractory disease (58) from sibling (87), and HLA-matched (42) or mismatched (17) unrelated and alternative donors (5). High-dose fractionated TBI-based conditioning was administered in 84. No differences were observed in baseline characteristics, except for disease stage at transplant, donor type, and graft source. With a follow-up of 19.0 (0.5-170.5) in TBI and 14.5 (1.2-319.1) months in non-TBI patients, there was no difference in acute (grades II-IV) or chronic GVHD, thrombotic microangiopathy, and bacterial or fungal infections. Only viral infections were significantly increased in the non-TBI group. There was no significant difference in the cumulative incidence (CI) of treatment-related or relapse mortality and disease-free or overall survival (OS). In the multivariate analysis, unfavorable pre-transplant predictors of OS were age (p = 0.024), advanced disease stage (p = 0.007), and female-to-male donor (p = 0.006). Interestingly, TBI patients younger than 40 years had significantly higher OS (55.1%, p = 0.023) and DFS (48.6%, p = 0.020). In conclusion, high-dose TBI is feasible in younger patients providing better survival. The choice between TBI- or Bu-conditioning regimens remains challenging. |
Databáze: | OpenAIRE |
Externí odkaz: |